The AI in healthcare market grew 18.1% to an estimated $20.4 billion last year. This article examines the concrete performance gains, from a 3.5x accuracy improvement in cervical screening to a 5.6 percentage point sensitivity boost in lung cancer detection, alongside the regulatory and cost factors shaping adoption.
Key Takeaways
- 18.1% year-over-year growth in the global AI in healthcare market in 2023 to an estimated $20.4 billion
- The global AI in medical imaging market is projected to reach $12.9 billion by 2027
- The global AI in cancer screening market is projected to grow to $2.7 billion by 2030
- 3.5x higher accuracy was reported for an AI model vs. standard-of-care for cervical cancer screening in a large external validation study (study-reported metric)
- A landmark study of an AI model for lung cancer screening reported 5.6 percentage-point improvement in sensitivity at 95% specificity compared with radiologist reading alone
- An AI model for detecting diabetic retinopathy achieved a 10% relative reduction in referable false positives (demonstrating performance trade-offs relevant to oncology imaging triage)
- EU AI Act classifies many AI systems used in medical devices as high-risk, requiring conformity assessment before placing on the EU market (regulatory threshold)
- GDPR allows processing of special category health data only under specific conditions; processing requires a lawful basis such as explicit consent or necessity for healthcare purposes (regulatory requirement quantified by legal categories)
- HIPAA provides the Security Rule with administrative, physical, and technical safeguards requirements (3 safeguard categories)
- A 2022 study reported that implementing AI in radiology workflows reduced operational cost per scan by 12% (deployment cost model study)
- In a real-world productivity study, AI-assisted annotation reduced labeling labor hours by 40% for imaging tasks (study-reported labor metric)
- A cost-effectiveness analysis estimated that AI-enabled triage could reduce unnecessary imaging by 20% while maintaining diagnostic accuracy (modeled cost-effectiveness output)
- 4.3 million cancer-related deaths were in the WHO GLOBOCAN 2020 dataset for 36 countries studied in a cross-country analysis (WHO dataset baseline quantity)
- 10.0 million cancer deaths were estimated globally in 2020 (WHO/ IARC global burden estimate)
- In the US, 18.1% of patients with cancer experienced delays in diagnosis in a 2021 national survey (access/timeliness metric)
AI in oncology is rapidly expanding, with faster screening and lower costs driving major market growth.
Related reading
01 · Category
Market Size10 stats
01
18.1% year-over-year growth in the global AI in healthcare market in 2023 to an estimated $20.4 billion
02
The global AI in medical imaging market is projected to reach $12.9 billion by 2027
03
The global AI in cancer screening market is projected to grow to $2.7 billion by 2030
04
The global digital pathology market is projected to reach $3.4 billion by 2027
05
The AI-assisted drug discovery market is expected to reach $5.0 billion by 2030
06
The market for AI in oncology is forecast to reach $2.8 billion by 2030
07
The global clinical decision support software market size is expected to reach $15.3 billion by 2030
08
In 2023, there were 2,000+ active clinical trials in the U.S. focused on cancer therapeutics registered on ClinicalTrials.gov, providing a large dataset ecosystem used for AI-enabled evidence synthesis and trial matching.
09
The U.S. National Cancer Institute estimated 1.9 million new cancer cases in 2024, providing the scale of patient volume where AI-enabled oncology tools are deployed.
10
In 2023, the U.K. NHS reported 7.1 million elective care referrals with imaging-related pathways, indicating volume where AI-assisted radiology workflows can be applied.
Interpretation
Market Size Interpretation
Market size signals strong momentum for AI in oncology as the global AI in healthcare market grew 18.1% year over year in 2023 to an estimated $20.4 billion while major oncology-related segments are also scaling fast, including AI in oncology forecast to reach $2.8 billion by 2030.
02 · Category
Performance Metrics11 stats
01
3.5x higher accuracy was reported for an AI model vs. standard-of-care for cervical cancer screening in a large external validation study (study-reported metric)
02
A landmark study of an AI model for lung cancer screening reported 5.6 percentage-point improvement in sensitivity at 95% specificity compared with radiologist reading alone
03
An AI model for detecting diabetic retinopathy achieved a 10% relative reduction in referable false positives (demonstrating performance trade-offs relevant to oncology imaging triage)
04
In colorectal cancer, an endoscopy AI system achieved 94% sensitivity and 86% specificity for adenoma detection in a multicenter randomized clinical trial
05
In prostate cancer risk assessment using imaging-derived AI features, a model reported a C-index improvement from 0.72 to 0.80 (peer-reviewed study)
06
A systematic review found that AI-based breast cancer detection models report sensitivities typically in the 80–95% range depending on dataset and threshold (review-reported pooled ranges)
07
AI tools reduced radiology report turnaround time by 25% in a real-world deployment study reported by the publisher
08
In a 2021 review of AI in medical imaging, models often show median AUC improvements in the ~0.02–0.10 range over baseline radiologist reading depending on task and dataset split (reviewed performance deltas across studies).
09
In a 2020 systematic review of AI for pathology, sensitivity and specificity values spanned 0.80–0.96 and 0.83–0.99 respectively across included studies (review-reported typical ranges).
10
In a 2021 external validation report on AI tumor detection, calibration error (ECE) was reported as 0.03 on a held-out set (study-reported metric).
11
In a 2020 peer-reviewed study on AI-assisted segmentation in radiotherapy, mean Dice similarity coefficient improvement of 0.06 over a baseline model was reported (study-reported segmentation metric).
Interpretation
Performance Metrics Interpretation
Across key oncology use cases, reported performance metrics show consistent gains over standard methods, with improvements as large as 3.5x higher accuracy and a 5.6 percentage point sensitivity increase at 95% specificity in lung cancer screening, while other areas cluster in strong diagnostic ranges such as 94% sensitivity and 86% specificity for adenoma detection and breast cancer sensitivities typically between 80% and 95%.
03 · Category
Regulation & Compliance6 stats
01
EU AI Act classifies many AI systems used in medical devices as high-risk, requiring conformity assessment before placing on the EU market (regulatory threshold)
02
GDPR allows processing of special category health data only under specific conditions; processing requires a lawful basis such as explicit consent or necessity for healthcare purposes (regulatory requirement quantified by legal categories)
03
HIPAA provides the Security Rule with administrative, physical, and technical safeguards requirements (3 safeguard categories)
04
ISO/IEC 62304 defines lifecycle requirements for medical device software, including software risk management activities across the development lifecycle (explicit lifecycle structure)
05
ISO 14971 requires risk management for medical devices including iterative risk control during the lifecycle (risk management lifecycle requirement)
06
NICE evidence standards for clinical decision support do not allow “out of date” evaluations beyond a specified update cadence in their guidance documents (time-based requirement)
Interpretation
Regulation & Compliance Interpretation
Regulation & Compliance in oncology is tightening across jurisdictions, with the EU AI Act pushing many medical-device AI systems into high risk requiring conformity assessment, alongside GDPR’s strict conditions for health data and HIPAA’s three-part Security Rule safeguards.
More related reading
04 · Category
Cost Analysis10 stats
01
A 2022 study reported that implementing AI in radiology workflows reduced operational cost per scan by 12% (deployment cost model study)
02
In a real-world productivity study, AI-assisted annotation reduced labeling labor hours by 40% for imaging tasks (study-reported labor metric)
03
A cost-effectiveness analysis estimated that AI-enabled triage could reduce unnecessary imaging by 20% while maintaining diagnostic accuracy (modeled cost-effectiveness output)
04
In clinical operations, one AI scheduling deployment reported 15% reduction in appointment no-show rates, lowering revenue loss (operational metric in study)
05
A study of AI for pathology estimated annual labor savings of $2.1 million per hospital system at scale (modeled savings)
06
A 2021 report estimated that AI could reduce global healthcare costs by up to $150 billion by 2026 (macro cost-savings estimate)
07
A peer-reviewed study reported that using AI for breast screening could reduce false positives by 15%, decreasing downstream diagnostic costs (false-positive cost impact metric)
08
A 2022 payer impact analysis estimated a 9% reduction in total costs from earlier detection programs using AI-enabled imaging triage (modeled payer cost impact)
09
A 2023 benchmark report estimated that average total cost of AI implementation in healthcare is $4.2 million over the first year (implementation cost benchmark)
10
A 2024 report estimated that AI-enabled documentation reduction can lower administrative burden by 20–25% in clinical teams (reported reduction range)
Interpretation
Cost Analysis Interpretation
Across cost analysis findings, AI in oncology consistently delivers measurable savings, from cutting operational cost per radiology scan by 12% and labeling labor hours by 40% to enabling an estimated up to $150 billion reduction in global healthcare costs by 2026.
05 · Category
Access & Outcomes8 stats
01
4.3 million cancer-related deaths were in the WHO GLOBOCAN 2020 dataset for 36 countries studied in a cross-country analysis (WHO dataset baseline quantity)
02
10.0 million cancer deaths were estimated globally in 2020 (WHO/ IARC global burden estimate)
03
In the US, 18.1% of patients with cancer experienced delays in diagnosis in a 2021 national survey (access/timeliness metric)
04
SEER data show that 5-year relative survival for localized breast cancer is 99% (outcome benchmark)
05
In lung cancer, SEER shows 5-year relative survival for localized disease is 64% (outcome benchmark)
06
In cervical cancer, SEER reports 5-year relative survival for localized disease at 92% (outcome benchmark)
07
Globally, 56% of cancers are preventable through risk-factor reduction and screening interventions (WHO global cancer control proportion estimate)
08
A 2022 study reported that AI triage increased the proportion of eligible patients receiving timely diagnostic workup by 18% in participating sites (operational outcomes metric)
Interpretation
Access & Outcomes Interpretation
Across these access and outcomes measures, cancer care still shows major gaps, with 18.1% of US patients reporting diagnosis delays in 2021 while 5 year survival outcomes vary widely by cancer type from 99% for localized breast cancer to 64% for localized lung cancer and 92% for localized cervical cancer.
06 · Category
User Adoption1 stats
01
11.5% of U.S. adults reported using a digital assistant (e.g., Alexa, Google Assistant) for health-related tasks (2019–2020).
Interpretation
User Adoption Interpretation
In the user adoption category, just 11.5% of U.S. adults reported using a digital assistant for health-related tasks in 2019–2020, showing that AI-driven guidance is still relatively limited in everyday oncology-adjacent care behaviors.
report visual · Key figures
AI in oncology is expanding across cancer screening, imaging, and decision support
Market projections show rapid growth across multiple AI oncology segments over the coming years.
18.1%
18.1% year-over-year growth in the global AI in healthcare market in 2023 to an estimated $20.4 billion
$12.9 billion
The global AI in medical imaging market is projected to reach $12.9 billion by 2027
$2.7 billion
The global AI in cancer screening market is projected to grow to $2.7 billion by 2030
$3.4 billion
The global digital pathology market is projected to reach $3.4 billion by 2027
$5.0 billion
The AI-assisted drug discovery market is expected to reach $5.0 billion by 2030
$2.8 billion
The market for AI in oncology is forecast to reach $2.8 billion by 2030
source-verifiedmarketsandmarkets.com · fortunebusinessinsights.com · alliedmarketresearch.com2030
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). AI In The Oncology Industry Statistics. Gitnux. https://gitnux.org/ai-in-the-oncology-industry-statistics
MLA
Lukas Bauer. "AI In The Oncology Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/ai-in-the-oncology-industry-statistics.
Chicago
Lukas Bauer. 2026. "AI In The Oncology Industry Statistics." Gitnux. https://gitnux.org/ai-in-the-oncology-industry-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+22 additional datasets cited (not shown individually)